
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
FDA proposals for expanding the pediatric study program include tax incentives and }transferable exclusivity.}
over 25 years ago
Research: New Horizonsover 25 years ago
Earnings: Tough Times Aheadover 25 years ago
Outbreak: Anthrax Alarmover 25 years ago
Patents: China on the Genome Mapover 25 years ago
Lilly's International Familyover 25 years ago
Update: Punishment and Reprieveover 25 years ago
Shortage: Vaccine Worriesover 25 years ago
Gateway to Japanover 25 years ago
Surrounded





